Market Analysis and Price Projections for NDC: 29300-0191
Introduction
The drug with the National Drug Code (NDC) 29300-0191 is Losartan Potassium and Hydrochlorothiazide, a combination medication used to treat high blood pressure. This analysis will delve into the market dynamics, price trends, and projections for this drug.
Market Context
Losartan Potassium and Hydrochlorothiazide is a generic version of the brand-name drug Hyzaar, which is widely used for the treatment of hypertension. The market for antihypertensive drugs is large and growing, driven by the increasing prevalence of hypertension globally.
Manufacturer Overview
The drug with NDC 29300-0191 is manufactured by Unichem Pharmaceuticals (USA), Inc., a company that produces a range of generic pharmaceuticals. Unichem Pharmaceuticals has a diverse portfolio of drugs, including several antihypertensive medications[1].
Pricing Trends
Pricing trends for generic drugs like Losartan Potassium and Hydrochlorothiazide are influenced by several factors, including competition, regulatory changes, and market demand.
Historical Pricing
Generic drugs typically experience a significant reduction in price once the patent for the brand-name drug expires and multiple generic versions enter the market. For Losartan Potassium and Hydrochlorothiazide, prices have generally decreased over time due to increased competition among generic manufacturers.
Current Pricing
As of recent data, the prices of generic antihypertensive drugs, including Losartan Potassium and Hydrochlorothiazide, have been relatively stable but subject to fluctuations based on market conditions. The Wholesale Acquisition Cost (WAC) or list price for these drugs can vary, but they are generally much lower than their brand-name counterparts[2].
Future Projections
Given the competitive nature of the generic drug market, prices for Losartan Potassium and Hydrochlorothiazide are expected to remain stable or decrease slightly over the next few years. Here are some key factors influencing future price projections:
Competition
The presence of multiple generic manufacturers will continue to drive competition, which typically leads to lower prices. As more manufacturers enter the market, the pricing pressure increases, benefiting consumers.
Regulatory Environment
Changes in regulatory policies, such as those related to drug pricing and negotiation programs (e.g., the Medicare Drug Price Negotiation Program), can impact the pricing of prescription drugs. For instance, the Medicare Drug Price Negotiation Program aims to reduce prices for certain high-expenditure drugs, which could indirectly influence the pricing of related generic medications[2].
Market Demand
The demand for antihypertensive drugs is expected to remain high due to the prevalence of hypertension. However, this demand is unlikely to drive significant price increases for generic versions like Losartan Potassium and Hydrochlorothiazide.
Market Analysis
Market Size and Growth
The global market for antihypertensive drugs is substantial and growing. While specific data for Losartan Potassium and Hydrochlorothiazide is not readily available, the overall market for hypertension treatments is projected to continue growing due to demographic changes and increasing awareness of hypertension.
Competitive Landscape
The competitive landscape for generic antihypertensive drugs is highly fragmented, with numerous manufacturers competing for market share. Unichem Pharmaceuticals, along with other generic drug manufacturers, faces competition from both established players and new entrants.
Customer Base
The customer base for Losartan Potassium and Hydrochlorothiazide includes patients with hypertension, healthcare providers, and payers such as insurance companies and government programs. The affordability of the drug is crucial for patient adherence and market acceptance.
Price Negotiation and Affordability
Medicare Drug Price Negotiation Program
While the Medicare Drug Price Negotiation Program primarily targets high-expenditure, single-source drugs, its impact on the broader pharmaceutical market can influence pricing strategies for generic drugs. The program's goal of reducing drug prices can create a ripple effect, making prescription drugs more affordable for a wider population[2].
Impact on Affordability
The affordability of Losartan Potassium and Hydrochlorothiazide is critical for its market success. Lower prices make the drug more accessible to patients, which can lead to higher market penetration and patient adherence.
Key Takeaways
- Stable Pricing: Prices for Losartan Potassium and Hydrochlorothiazide are expected to remain stable or decrease slightly due to competition and regulatory pressures.
- Market Growth: The overall market for antihypertensive drugs is growing, driven by the increasing prevalence of hypertension.
- Competition: The generic drug market is highly competitive, with multiple manufacturers influencing pricing dynamics.
- Affordability: Affordability is a key factor in the market success of Losartan Potassium and Hydrochlorothiazide, with lower prices enhancing patient access and adherence.
FAQs
What is the NDC 29300-0191?
The NDC 29300-0191 corresponds to the drug Losartan Potassium and Hydrochlorothiazide, a combination medication used to treat high blood pressure.
Who manufactures this drug?
The drug is manufactured by Unichem Pharmaceuticals (USA), Inc.
What are the key factors influencing the price of this drug?
Key factors include competition among generic manufacturers, regulatory changes, and market demand.
How does the Medicare Drug Price Negotiation Program affect generic drug prices?
While the program primarily targets high-expenditure drugs, it can create a broader impact on the pharmaceutical market, potentially influencing pricing strategies for generic drugs.
What is the expected market trend for antihypertensive drugs?
The market for antihypertensive drugs is expected to continue growing due to the increasing prevalence of hypertension.
How does competition affect the pricing of Losartan Potassium and Hydrochlorothiazide?
Competition among multiple generic manufacturers drives pricing pressure, leading to stable or decreasing prices over time.
Sources
- Find-A-Code: Unichem Pharmaceuticals (USA), Inc. - List of Drugs.
- ASPE - HHS.gov: Medicare Drug Price Negotiation Program.
- GlobalData: NSCLC Market - Global Drug Forecast & Market Analysis to 2025.
- FDA: National Drug Code Directory.
